Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
55 shown of 6,411 total abstracts
  1. Abstract 64852026-06-01 · 15:00 CT · Arie Crown Theater
    Quality of life outcomes with Keytruda in patients with RCC
    S. Modi, N. Rizvi, J. Cortes, et al. · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract 64872026-06-01 · 15:00 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-898
    N. Rizvi, S. Peters · Memorial Sloan Kettering Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract 64212026-06-01 · 14:45 CT · Arie Crown Theater
    Quality of life outcomes with Opdivo in patients with RCC
    S. Peters, M. Reck · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract 60292026-06-01 · 16:15 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-35 study)
    S. Peters, H. Rugo, S. Modi · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract 61122026-06-02 · 21:30 CT · E450
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-984
    M.C. Garassino, R. Herbst · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  6. Abstract 62212026-06-05 · 15:45 CT · S406
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-909 study)
    R. Herbst, T. Mok, C. Robert, et al. · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  7. Abstract 63302026-06-01 · 15:15 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-425 study)
    M.C. Garassino, T. Mok · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  8. Abstract 63862026-06-02 · 19:45 CT · S406
    CheckMate-708: Opdivo (nivolumab) 1L in RCC
    G. Curigliano, H. Borghaei, L. Paz-Ares, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  9. Abstract 65402026-06-04 · 18:15 CT · Hall B1
    Real-world effectiveness of Opdivo vs standard of care in RCC
    J. Brahmer, M. Reck, S. Modi, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  10. Abstract 60962026-06-03 · 18:15 CT · S406
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-87
    F. Andre, P. Schmid, E. Winer, et al. · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  11. Abstract 69852026-06-03 · 14:30 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-539
    P. Schmid, N. Rizvi, J. Cortes · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  12. Abstract 67672026-06-04 · 19:00 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-167
    M. Reck, M.C. Garassino, F. Andre · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  13. Abstract 69022026-06-04 · 15:00 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-354
    C. Saura, M. Reck, F. Andre, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  14. Abstract 69162026-06-05 · 19:00 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-417 study)
    R. Herbst, S. Peters, S. Tolaney, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  15. Abstract 66562026-06-02 · 21:30 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-54
    A. Spira, H. Rugo, P. Schmid · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  16. Abstract 60642026-06-05 · 21:30 CT · E450
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-461 study)
    S. Modi, M. Krop · Princess Margaret Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  17. Abstract 60152026-06-04 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-549 study)
    J. Cortes, N. Rizvi, S. Tolaney, et al. · MD Anderson Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  18. Abstract 68242026-06-01 · 18:15 CT · S406
    Long-term follow-up of Keytruda adjuvant for RCC: KEYNOTE-947
    H. Borghaei, S. Modi, R. Herbst, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  19. Abstract 67372026-06-01 · 15:00 CT · S406
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-384
    J. Cortes, F. Andre · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  20. Abstract 60182026-06-02 · 13:45 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-686 study)
    P. Schmid, J. Brahmer, S. Modi, et al. · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  21. Abstract 61672026-06-03 · 21:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-912 study)
    C. Robert, T. Mok, J. Brahmer, et al. · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  22. Abstract 63582026-06-05 · 16:15 CT · E450
    Long-term follow-up of Opdivo 1L for RCC: CheckMate-174
    S. Peters, E. Winer, H. Borghaei · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  23. Abstract 69642026-06-05 · 21:30 CT · Arie Crown Theater
    CheckMate-649: Opdivo (nivolumab) maintenance in RCC
    S. Antonia, T. Mok, S. Modi · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  24. Abstract 61402026-06-02 · 15:15 CT · E450
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-249 study)
    E. Winer, A. Spira · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  25. Abstract 60142026-06-03 · 15:45 CT · Hall B1
    CheckMate-324: Opdivo (nivolumab) neoadjuvant in RCC
    S. Peters, F. Andre, M. Krop · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  26. Abstract 64542026-06-03 · 14:00 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in RCC
    J. Cortes, H. Borghaei · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  27. Abstract 68652026-06-02 · 14:45 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-227
    C. Robert, A. Spira · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  28. Abstract 66652026-06-04 · 16:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-349
    H. Borghaei, S. Antonia, E. Winer, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  29. Abstract 61212026-06-05 · 21:00 CT · S406
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-110
    M. Krop, S. Peters, C. Saura, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  30. Abstract 68082026-06-02 · 18:00 CT · Hall B1
    KEYNOTE-603: Keytruda (pembrolizumab) 2L in RCC
    F. Andre, M.C. Garassino, M. Krop, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  31. Abstract 65892026-06-04 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-795 study)
    M.C. Garassino, S. Antonia, C. Saura, et al. · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  32. Abstract 62682026-06-02 · 21:30 CT · S406
    CheckMate-798: Opdivo (nivolumab) neoadjuvant in RCC
    S. Modi, T. Mok, F. Andre, et al. · Cleveland Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  33. Abstract 69942026-06-01 · 18:45 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-330
    E. Winer, C. Saura, G. Curigliano, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  34. Abstract 69612026-06-04 · 18:15 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-723
    C. Robert, N. Rizvi, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  35. Abstract 69782026-06-02 · 19:00 CT · S100A
    Long-term follow-up of Keytruda 1L for RCC: KEYNOTE-410
    R. Herbst, M.C. Garassino, J. Cortes · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  36. Abstract 66732026-06-01 · 19:15 CT · S406
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-852
    G. Curigliano, H. Rugo, J. Brahmer · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  37. Abstract 61032026-06-01 · 14:00 CT · S406
    CheckMate-364: Opdivo (nivolumab) neoadjuvant in RCC
    L. Paz-Ares, S. Antonia, M.C. Garassino, et al. · Dana-Farber Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  38. Abstract 68912026-06-04 · 15:15 CT · S100A
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-715
    S. Modi, S. Peters, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  39. Abstract 60202026-06-02 · 14:00 CT · S406
    Long-term follow-up of Keytruda 3L+ for RCC: KEYNOTE-419
    M.C. Garassino, S. Peters, G. Curigliano, et al. · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  40. Abstract 67332026-06-05 · 18:15 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-103
    M.C. Garassino, M. Krop, H. Borghaei · Mayo Clinic
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  41. Abstract 65052026-06-02 · 20:00 CT · Hall B1
    Long-term follow-up of Opdivo neoadjuvant for RCC: CheckMate-377
    M.C. Garassino, E. Winer · Johns Hopkins Kimmel Cancer Center
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  42. Abstract 69202026-06-01 · 18:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-591
    P. Schmid, N. Rizvi · Vall d'Hebron Institute of Oncology
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  43. Abstract 64982026-06-02 · 15:00 CT · S406
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-731
    J. Brahmer, L. Paz-Ares, S. Peters · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  44. Abstract 68552026-06-04 · 13:15 CT · Arie Crown Theater
    CheckMate-540: Opdivo (nivolumab) adjuvant in RCC
    C. Saura, E. Winer · Chinese University of Hong Kong
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  45. Abstract 60372026-06-05 · 19:00 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-344 study)
    E. Winer, M.C. Garassino, S. Modi, et al. · National Cancer Center Japan
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  46. Abstract 65102026-06-01 · 19:00 CT · S406
    Biomarker subgroup analysis of Keytruda in RCC (the KEYNOTE-235 study)
    J. Brahmer, F. Andre · Royal Marsden Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  47. Abstract 60172026-06-03 · 20:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-30
    T. Mok, C. Robert, R. Herbst · Massachusetts General Hospital
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  48. Abstract 65392026-06-01 · 19:30 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-438
    S. Modi, F. Andre · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  49. Abstract 64792026-06-01 · 15:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-318
    M. Reck, C. Saura, J. Brahmer, et al. · Peter MacCallum Cancer Centre
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  50. Abstract 66762026-06-03 · 21:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-629
    J. Cortes, S. Peters, H. Borghaei, et al. · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  51. Abstract 61002026-06-05 · 18:45 CT · Arie Crown Theater
    CheckMate-568: Opdivo (nivolumab) maintenance in RCC
    S. Peters, E. Winer · Stanford Cancer Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  52. Abstract 62402026-06-02 · 13:00 CT · S406
    CheckMate-144: Opdivo (nivolumab) adjuvant in RCC
    T. Mok, F. Andre, R. Herbst · Karolinska Institute
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  53. Abstract 66992026-06-01 · 16:00 CT · E450
    Long-term follow-up of Opdivo 3L+ for RCC: CheckMate-542
    S. Tolaney, E. Winer, G. Curigliano · University of Chicago
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  54. Abstract 66912026-06-04 · 21:30 CT · Hall B1
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-307
    N. Rizvi, S. Modi, H. Borghaei, et al. · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  55. Abstract 68352026-06-03 · 19:00 CT · S406
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-232
    S. Peters, H. Borghaei · Institut Gustave Roussy
    Poster SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.